Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.

Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, Findeli A, Vorburger F, Quemeneur E, Erbs P.

Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27.

2.

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Kleinpeter P, Remy-Ziller C, Winter E, Gantzer M, Nourtier V, Kempf J, Hortelano J, Schmitt D, Schultz H, Geist M, Brua C, Hoffmann C, Schlesinger Y, Villeval D, Thioudellet C, Erbs P, Foloppe J, Silvestre N, Fend L, Quemeneur E, Marchand JB.

J Virol. 2019 May 15;93(11). pii: e00207-19. doi: 10.1128/JVI.00207-19. Print 2019 Jun 1.

3.

Oncolytic properties of non-vaccinia poxviruses.

Ricordel M, Foloppe J, Pichon C, Findeli A, Tosch C, Cordier P, Cochin S, Quémeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Oncotarget. 2018 Nov 13;9(89):35891-35906. doi: 10.18632/oncotarget.26288. eCollection 2018 Nov 13.

4.

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.

Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P.

Cancers (Basel). 2018 Jul 10;10(7). pii: E231. doi: 10.3390/cancers10070231.

5.

Cowpox Virus: A New and Armed Oncolytic Poxvirus.

Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, Cochin S, Cordier P, Quemeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Mol Ther Oncolytics. 2017 Aug 24;7:1-11. doi: 10.1016/j.omto.2017.08.003. eCollection 2017 Dec 15.

6.

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.

Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K.

Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18.

7.

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.

Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Préville X.

J Immunother Cancer. 2017 Sep 19;5(1):70. doi: 10.1186/s40425-017-0274-x.

8.

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.

Bendjama K, Quemeneur E.

Hum Vaccin Immunother. 2017 Sep 2;13(9):1997-2003. doi: 10.1080/21645515.2017.1334746. Epub 2017 Aug 28.

9.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L.

Cancer Res. 2017 Aug 1;77(15):4146-4157. doi: 10.1158/0008-5472.CAN-16-2165. Epub 2017 May 23.

10.

Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.

Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P.

J Immunother Cancer. 2017 Jan 17;5:4. doi: 10.1186/s40425-016-0204-3. eCollection 2017.

11.

[Nursing practice within the French national gendarmerie intervention group].

Fressancourt Y, Quémeneur É, Bertho K, Dubourg O.

Rev Infirm. 2016 Nov;65(225):22-24. doi: 10.1016/j.revinf.2016.08.025. French.

PMID:
27968965
12.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB.

Oncoimmunology. 2016 Sep 9;5(10):e1220467. eCollection 2016.

13.

Characterization of UO2(2+) binding to osteopontin, a highly phosphorylated protein: insights into potential mechanisms of uranyl accumulation in bones.

Qi L, Basset C, Averseng O, Quéméneur E, Hagège A, Vidaud C.

Metallomics. 2014 Jan;6(1):166-76. doi: 10.1039/c3mt00269a.

PMID:
24327307
14.

Antibody-free detection of phosphoserine/threonine containing peptides by homogeneous time-resolved fluorescence.

Alpha-Bazin B, Quéméneur E.

Anal Chem. 2012 Nov 20;84(22):9963-70. doi: 10.1021/ac3021505. Epub 2012 Oct 30.

PMID:
23110758
15.

From cell to man: evaluation of osteopontin as a possible biomarker of uranium exposure.

Prat O, Ansoborlo E, Sage N, Cavadore D, Lecoix J, Kurttio P, Quemeneur E.

Environ Int. 2011 May;37(4):657-62. doi: 10.1016/j.envint.2011.01.004. Epub 2011 Feb 16.

PMID:
21324525
16.

Predicting the disruption by UO2(2+) of a protein-ligand interaction.

Pible O, Vidaud C, Plantevin S, Pellequer JL, Quéméneur E.

Protein Sci. 2010 Nov;19(11):2219-30. doi: 10.1002/pro.501.

17.

Characterisation of the purified human sodium/iodide symporter reveals that the protein is mainly present in a dimeric form and permits the detailed study of a native C-terminal fragment.

Huc-Brandt S, Marcellin D, Graslin F, Averseng O, Bellanger L, Hivin P, Quemeneur E, Basquin C, Navarro V, Pourcher T, Darrouzet E.

Biochim Biophys Acta. 2011 Jan;1808(1):65-77. doi: 10.1016/j.bbamem.2010.08.013. Epub 2010 Aug 23.

18.

One step immunochromatographic assay for the rapid detection of Alexandrium minutum.

Gas F, Baus B, Pinto L, Compere C, Tanchou V, Quéméneur E.

Biosens Bioelectron. 2010 Jan 15;25(5):1235-9. doi: 10.1016/j.bios.2009.09.033. Epub 2009 Oct 1.

PMID:
19857953
19.

Alterations in gene expression in cultured human cells after acute exposure to uranium salt: Involvement of a mineralization regulator.

Prat O, Bérenguer F, Steinmetz G, Ruat S, Sage N, Quéméneur E.

Toxicol In Vitro. 2010 Feb;24(1):160-8. doi: 10.1016/j.tiv.2009.07.035. Epub 2009 Aug 3.

PMID:
19654044
20.

Identification of uranyl binding proteins from human kidney-2 cell extracts by immobilized uranyl affinity chromatography and mass spectrometry.

Dedieu A, Bérenguer F, Basset C, Prat O, Quéméneur E, Pible O, Vidaud C.

J Chromatogr A. 2009 Jul 10;1216(28):5365-76. doi: 10.1016/j.chroma.2009.05.023. Epub 2009 May 18.

PMID:
19501829

Supplemental Content

Loading ...
Support Center